MIRA Pharmaceuticals, Inc. Price & Performance (MIRA)

MIRA Pharmaceuticals has finalized an agreement to acquire SKNY Pharmaceuticals in an all-stock transaction. This acquisition brings SKNY-1, an experimental oral drug for weight loss and smoking cessation, into MIRA’s pipeline. The deal includes a $5 million capital infusion, positioning MIRA to expand into lucrative pharmaceutical markets.123

MIRA Pharmaceuticals’ stock fell 8.6% premarket after announcing its acquisition of SKNY Pharmaceuticals. The transaction, executed through a stock swap, will integrate SKNY-1 into MIRA’s portfolio. Despite the decline, the deal adds a significant weight-loss and smoking cessation candidate to MIRA’s development efforts.134

The acquisition of SKNY Pharmaceuticals by MIRA Pharmaceuticals will enhance its portfolio with SKNY-1, a preclinical drug targeting obesity and smoking cessation. SKNY will contribute $5 million in assets or cash, bolstering MIRA’s financial standing. The transaction underscores MIRA’s strategic focus on high-growth therapeutic areas.234